Furthermore, the absence of DR5 in GFAP positive astroglial cells is linked to the expression of BNIP3, a transcriptional inhibitor, which mitigates DR5 expression and confers resistance to TRAIL in gliomas [105]. Here, BNIP3 is linked to central nervous system cancer.